We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tyme Technologies Inc New | NASDAQ:TYME | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.3107 | 0.29 | 0.299 | 0 | 01:00:00 |
TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET.
Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows:
Date:
Monday, November 8, 2021
Time:
8:30 AM ET
Toll-free (U.S.)
(866) 601-3896
International
(636) 812-6499
Conference ID
5953454
The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.
Following the Company’s presentation, there will be a Q&A session. Management will address both live questions and those submitted in advance via email to lwilson@insitecony.com. The deadline to submit questions for the conference call is 5:00 PM ET on November 4, 2021.
About TYME Technologies, Inc.
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of our emerging CMBT™ pipeline.
For more information, visit www.tymeinc.com. Follow us on social media: Facebook, LinkedIn, Twitter, YouTube and Instagram.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form
10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 10, 2021, as well as subsequent reports and filings from time to time with the SEC.
The information contained in this press release is as of release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005875/en/
INVESTORS AND MEDIA: In-Site Communications Lisa M. Wilson T: 212-452-2793 E: lwilson@insitecony.com
1 Year Tyme Technologies Chart |
1 Month Tyme Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions